Emerging data suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may represent a notable development for body loss . Early human investigations have demonstrated considerable reductions in visceral fat , possibly outperforming existing weight-loss medications . Nevertheless , additional e